KEEP UP WITH THE LATEST IN INDUSTRY NEWS!
From news about new medicines, pharmacy business insights, and the pharmaceutical industry in general—this is your source!
DrugTopics articles
- Q&A: CDC Alters COVID-19 Recommendations, Leading to Confusion on Pediatric Vaccine Schedules August 30, 2025Childhood immunization guidance in the US faces confusion as the AAP and CDC diverge on COVID-19 vaccine recommendations, impacting parents and providers.
- Q&A: Pharmacists at the Frontline of Health Literacy Challenges August 29, 2025Pharmacists are uniquely positioned to close health literacy gaps through clear communication and intentional patient education.
- Q&A: How Tragedy is Forcing Change in the PBM Industry August 29, 2025Bil Schmidtknecht joined Drug Topics to share his son’s tragic story and how it motivated him to join the greater fight in putting the lives of patients at the forefront of health care.
- ACIP and CDC Guidelines Prompt AAP to Update Immunization Schedule August 29, 2025Confusion arises as health organizations diverge on COVID-19 vaccine recommendations for children, highlighting the need for clear guidance and support.
- Influenza Vaccine Rates Increased Among Black, Hispanic Older Adults August 29, 2025Among older adults with Medicare, researchers investigated national influenza vaccination patterns by race, education level, and rurality.
- PCV10 Among Children Indirectly Protected Unvaccinated Adults August 28, 2025Researchers explored the impact of PCV10 on the distribution of invasive pneumococcal disease serotypes among patients in Lithuania.
- Independent, Chain Pharmacy Turnover Reflects Retail Business Churn August 28, 2025Addressing the impacts on patients and the overall pharmacy market, Joey Mattingly, PharmD, MBA, PhD, discusses trends in pharmacies opening and closing across the country.
- FDA Approves First Generic GLP-1 Liraglutide for Weight Loss August 28, 2025Liraglutide is the first glucagon-like peptide-1 to have a generic equivalent for both type 2 diabetes and obesity indications.
- Optimizing Multidisciplinary Care August 28, 2025Panelists discuss how pharmacists can optimize multidisciplinary care for hypercortisolism by leveraging their training in chronic disease management and collaborative practice agreements to flag patients with persistent uncontrolled diabetes for screening, coordinate the diagnostic process and referrals to endocrinologists, and manage diabetes and hypertension while incorporating diabetes technology into treatment plans, and potentially oversee the […]
- FDA Approves COVID-19 Vaccines for Patients 65 Years and Older August 28, 2025The approved vaccines include Novavax’s Nuvaxovid and Moderna’s Spikevax and mNexspike.
Pharmacy Times articles
- Expert: Pharmacists Are Critical in Combating Vaccine Hesitancy, Improving Childhood Immunization August 30, 2025Allison Hill, PharmD, RPh explains how pharmacists’ accessibility and trusted relationships make them key to combatting vaccine hesitancy.
- Protecting Community Oncology Practices in the Wake of the IRA August 29, 2025Explore the impact of the Inflation Reduction Act on community oncology practices and discover how new legislation aims to protect patient access to care.
- Expert: Pharmacists Play Key Role in Expanding RSV Vaccine Awareness, Adult Immunization Efforts August 29, 2025Alyssa Modic, PharmD, discusses the evolving role of pharmacists in adult immunizations and strategies to improve respiratory syncytial virus (RSV) vaccine education and uptake.
- Updated Diabetes Guidelines Prioritize SGLT-2 and GLP-1 Medications to Reduce Cardiovascular, Kidney Risk August 29, 2025An international BMJ panel recommended broader use of SGLT-2 inhibitors and GLP-1 receptor agonists.
- FDA Approves 3-Month Leuprolide Mesylate 21 mg Formulation for Advanced Prostate Cancer August 29, 2025The FDA has approved a ready-to-use long-acting injectable formulation that is administered every 3 months as a treatment for advanced prostate cancer.
- Many Patients With Statin Intolerance Self-Medicate, Despite No Link to Lowering LDL-C August 29, 2025Self-medication, including the use of dietary supplements and pain relief drugs, were reported by many patients with statin-associated muscle symptoms to lower their low-density lipoprotein cholesterol (LDL-C).
- The Role of LAIs in Schizophrenia: Convenience, Adherence, and Access August 29, 2025Explore the benefits and challenges of long-acting injectables (LAIs) in managing schizophrenia for improved patient outcomes.
- FluMist Home Delivery Expands Access to Seasonal Influenza Vaccination August 29, 2025FluMist Home, the first at-home nasal spray flu vaccine, is now available for direct delivery to patients in 34 US states.
- Iza-Bren Receives FDA Breakthrough Therapy Designation for EGFR-Mutated NSCLC August 29, 2025The action is supported by 3 ongoing clinical trials, which are evaluating izalontamab brengitecan (iza-bren) in non–small cell lung cancer (NSCLC) and other diseases.
- Study: Apitegromab Meaningfully Improves Motor Function in Spinal Muscular Atrophy August 29, 2025Results from the phase 3 SAPPHIRE trial show significant improvements in motor function in children and adults with spinal muscular atrophy.
Helping You Navigate the Returns Process!
Pedigree Statement
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with it’s clients…
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with its clients. This is to ensure that the reverse distribution portion of the supply chain that we service keeps its functionality and integrity for our customers and the public.
Several pedigree and distribution level issues have been raised in the industry. Discounted, indigent-pricing, short dated, bulk purchase, secondary distribution, or DSCSA non-compliant sales could affect the credit available for a product based on a manufacturers determination. We ask that you do not return these products for credit as they are not eligible in most cases. Flash Returns LLC may choose to dispose of these on the pharmacies behalf at no charge if the cost is low relative to the return. Most customers purchasing products from reputable wholesalers will not encounter these issues, however all pharmacies are asked to acknowledge our policy on pedigree and legitimacy of product here and by signing the PSA before a return is initiated.
Some manufacturers may require proof the price paid for a product and what wholesaler distributed the product. Issues causing triggering this could be: bulk or large quantities of single items or lots, or products purchased speculatively. In some cases we may request invoices from the customer to ensure Flash Returns or manufacturer policy is being met. If none are available or if the information isn’t accepted by the manufacturer it could cause the return to be non-returnable.
Flash Returns, LLC cannot guarantee or be liable for the value or credit for products that were purchased outside of manufacturer accepted distribution channels. This could include products: purchased from a wholesaler that is not an approved vendor, products not purchased directly from a particular manufacturer, purchased on a speculative basis, diverted or counterfeit products, foreign products, and any product purchased on a non-returnable basis, including short-dated product purchased at discounted pricing.
At any time, Flash Returns, LLC or a manufacturer may require invoices or pedigree information demonstrating proof of purchase. If product has been shipped by Flash Returns, LLC or the Customer to a manufacturer or their agent, Flash Returns, LLC cannot guarantee or facilitate the return of product to the Customer. Manufacturers reverse the right to destroy product they deem not credit worthy or suspect. Manufacturers agreeing to return product to customers will do so at the customers expense. Flash Returns, LLC shall not be responsible for reimbursing a Customer for such product.
If Customer is unable to have product returned within 21 days, product is subject to be destroyed without any payment or credit issued to Customer. In any dispute, failure by Customer to provide invoices for a product or pedigree if requested shall release Flash Returns, LLC from any and all liability of products involved in dispute including the full value of the product. More information on drug pedigrees is available on the FDA website at:
Pedigree Statement
P: 833.553.5274
E: SignUp@FlashReturns.com